According to research by nova one advisor, the global cell and gene therapy market size was valued at $18.13 billion in 2023 ...

On June 2, 2024, Caribou issued a press release announcing that it had "presented updated clinical data from the ongoing ANTLER Phase 1 trial that [purportedly] indicates a single dose of CB-010 . . .

Artiva Biotherapeutics, Inc.’s ARTV share price has dipped by 15.00%, which has investors questioning if this is right time ...

CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or the "Company") today released a letter to shareholders from the Chairman of the Company's Board ...

Trenchant partnered with Autolomous, integrating its digital solution into its CGT manufacturing platform, for faster production and lower costs.

Senti Bio aims to improve cancer therapeutics with customizable gene circuits, or multi-gene constructs capable of ...

Fate Therapeutics uses iPSC and gene editing to offer scalable off-the-shelf therapies. Read more to see why I rate FATE ...

Personalized medicine advances as autologous cell therapy grows, leveraging refined cell collection, improved processing ...

Engineered immune cells called CAR-T cells are used in the treatment of cancer. Researchers from Uppsala University have now ...

Name any acne treatment and I guarantee I have tried it. I suffered from horrific breakouts during my teens, and though a healthy dose of Accutane rescued my complexion, I still battle with angry ...

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company with a market capitalization of $156.6 million, is at a pivotal juncture in its development of programmed cellular ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...